Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
Cosmo (OTC:CMOPF) has announced the sale of its "Digital Trust" business to Tinexta InfoCert for €8.3 million. The transaction, expected to close by end of June 2025, involves the divestment of digital security services focused on identity protection and process dematerialization for healthcare organizations.
This strategic move is part of Cosmo's portfolio streamlining initiative, allowing the company to focus on core business areas including AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services. The company aims to strengthen its position as a focused, innovation-driven healthcare organization with global reach.
Cosmo (OTC:CMOPF) ha annunciato la cessione della sua divisione "Digital Trust" a Tinexta InfoCert per 8,3 milioni di euro. L'operazione, che si prevede si concluda entro la fine di giugno 2025, riguarda la vendita dei servizi di sicurezza digitale dedicati alla protezione dell'identità e alla dematerializzazione dei processi per le organizzazioni sanitarie.
Questa mossa strategica fa parte dell'iniziativa di razionalizzazione del portafoglio di Cosmo, permettendo all'azienda di concentrarsi sulle aree di business principali, tra cui dispositivi medici basati sull'intelligenza artificiale, terapie gastrointestinali, dermatologia e servizi CDMO ad alto valore aggiunto. L'obiettivo è rafforzare la posizione dell'azienda come realtà sanitaria innovativa e focalizzata, con una presenza globale.
Cosmo (OTC:CMOPF) ha anunciado la venta de su negocio de "Digital Trust" a Tinexta InfoCert por 8,3 millones de euros. La transacción, que se espera cerrar para finales de junio de 2025, implica la desinversión en servicios de seguridad digital centrados en la protección de identidad y la desmaterialización de procesos para organizaciones sanitarias.
Esta decisión estratégica forma parte de la iniciativa de Cosmo para simplificar su cartera, permitiendo a la empresa centrarse en sus áreas principales, incluyendo dispositivos médicos impulsados por inteligencia artificial, terapias gastrointestinales, dermatología y servicios CDMO de alto valor. La compañía busca fortalecer su posición como una organización sanitaria innovadora y enfocada con alcance global.
Cosmo (OTC:CMOPF)는 Tinexta InfoCert에 "Digital Trust" 사업부를 830만 유로에 매각한다고 발표했습니다. 이 거래는 2025년 6월 말까지 완료될 예정이며, 의료 기관을 위한 신원 보호 및 프로세스 디지털화에 중점을 둔 디지털 보안 서비스의 매각을 포함합니다.
이번 전략적 결정은 Cosmo의 포트폴리오 정리 계획의 일환으로, 회사가 인공지능 기반 의료기기, 위장 치료, 피부과 및 고부가가치 CDMO 서비스 등 핵심 사업 분야에 집중할 수 있도록 합니다. 회사는 혁신 중심의 전문 의료 기관으로서 글로벌 입지를 강화하는 것을 목표로 하고 있습니다.
Cosmo (OTC:CMOPF) a annoncé la vente de son activité "Digital Trust" à Tinexta InfoCert pour 8,3 millions d'euros. La transaction, qui devrait être finalisée d'ici fin juin 2025, concerne la cession des services de sécurité numérique axés sur la protection de l'identité et la dématérialisation des processus pour les organisations de santé.
Cette décision stratégique s'inscrit dans le cadre de la simplification du portefeuille de Cosmo, permettant à l'entreprise de se concentrer sur ses activités principales, notamment les dispositifs médicaux à intelligence artificielle, les thérapeutiques gastro-intestinales, la dermatologie et les services CDMO à forte valeur ajoutée. L'objectif est de renforcer sa position en tant qu'organisation de santé innovante et spécialisée, avec une portée mondiale.
Cosmo (OTC:CMOPF) hat den Verkauf seines "Digital Trust"-Geschäfts an Tinexta InfoCert für 8,3 Millionen Euro bekannt gegeben. Die Transaktion, die voraussichtlich bis Ende Juni 2025 abgeschlossen sein wird, umfasst den Verkauf von digitalen Sicherheitsdienstleistungen, die sich auf Identitätsschutz und Prozessdigitalisierung für Gesundheitsorganisationen konzentrieren.
Dieser strategische Schritt ist Teil der Portfolio-Optimierung von Cosmo und ermöglicht es dem Unternehmen, sich auf Kernbereiche wie KI-gestützte medizinische Geräte, gastrointestinale Therapien, Dermatologie und hochwertige CDMO-Dienstleistungen zu fokussieren. Das Unternehmen strebt an, seine Position als innovationsgetriebenes, spezialisiertes Gesundheitsunternehmen mit globaler Reichweite zu stärken.
- Sale of non-core asset generates €8.3 million in revenue
- Strategic focus on high-impact core businesses including AI-powered medical devices
- Streamlined portfolio enables better capital allocation to priority growth areas
- Divestment of revenue-generating digital security business unit
- Reduction in business diversification
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo.
“Digital Trust” provides services within the digital security sector, offering IT solutions for digital identity protection and process dematerialization for healthcare organizations.
The decision to sell “Digital Trust” is part of a broader effort to streamline the Company’s portfolio and reinforce its position as a focused, performance-driven organization. Cosmo is executing a clear strategic direction – prioritizing growth in AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services – while actively reallocating capital to the areas with the highest impact.
“Digital Trust is not a strategic asset for Cosmo, and this transaction reflects our disciplined focus on what drives the greatest impact for patients and shareholders,” said Giovanni Di Napoli, CEO of Cosmo. “This is another concrete step forward in positioning Cosmo for sustainable growth by strengthening our focus on innovation and operational excellence in our core markets.”
Cosmo continues to execute its strategy to build a focused, innovation-driven healthcare company with global reach, leveraging its strong capabilities in R&D, AI integration, and commercial partnerships.
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Financial calendar
| Investor Day, Zurich | July 1, 2025 |
| 2025 Half-Year Results and Report | July 23, 2025 |
For further information, please contact:
Cosmo Pharmaceuticals Investor Relations, investor.relations@cosmopharma.com
About Tinexta InfoCert
Tinexta Infocert, part of the Tinexta Group, is the largest Certification Authority in Europe, operating in over 20 countries. The Company provides services in digitalization, eDelivery, Digital Signature, and digital document preservation. It is an AgID-accredited operator of digital identity within the framework of SPID (Public System for the Management of Digital Identity). It aims to continue expanding internationally also through acquisitions: it holds
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256766
FAQ
How much will Cosmo (CMOPF) receive from the Digital Trust sale?
When will Cosmo's Digital Trust sale transaction close?
What are Cosmo's core focus areas after the Digital Trust sale?
Who is buying Cosmo's Digital Trust business?
What is the strategic rationale behind Cosmo's Digital Trust sale?
